Design and Evaluation of Complex Sequential Analysis Trials
- Two Means - Simulation.nqt
- Group Sequential Test of Two Survival.nqt
- Two Sample Log Rank - Non-GSD.nqt
- Two Sample Log-Rank Test with Specified Rates using Simulation.nqt
- Log-Rank Test, User-Specified Accrual, Fixed Follow-up, Piecewise Survival and Dropout Rates.nqt
Design and Evaluation of Complex Sequential Analysis Trials
Sequential Survival Analysis and Simulation for Operating Characteristics
Sequential designs, where trials can stop early based on interim results, are the most widely used type of adaptive design in clinical trials.
However, sequential designs still require careful consideration of design choices, particularly in the context of more complex areas such as survival analysis. Simulation can be a vital tool to explore the performance of sequential designs over a wide range of scenarios.
You will learn about:
-
Sequential Design Overview
-
Group Sequential Designs for Survival Analysis
-
Simulation for Operating Characteristics of Sequential Designs
Design and Evaluation of Complex Sequential Analysis Trials
Sequential designs can greatly reduce the potential cost of a trial by stopping early where evidence is strongly in favour (efficacy) or against (futility) the treatment at an early interim analysis. For example, the accelerated approval of COVID-19 vaccine trials in 2020 were based on sequential design approaches.
A wide variety of methods are available for sequential designs such as error-spending, Haybittle-Peto and Wang-Tsiatis designs with careful consideration between these needed to justify design choices to sponsors and regulators.
These design choices are even more complicated when dealing with complex endpoints such as time-to-event where considerations such as accrual, hazard rates and dropout can have substantial effects on the statistical and practical aspects of study design.
Choosing between different sequential design choices can be difficult but simulation can be used to explore the performance of a sequential design under a wide variety of scenarios including different effect sizes, test statistic choices and stopping boundaries.
These simulations provide context on the expected probability of stopping for efficacy or futility at each interim analysis and the expected overall sample size that will be recruited for a sequential trial under those assumptions.
In this tutorial, we discussed the choices available for sequential designs, how sequential designs are adapted for complex endpoints such as time-to-event and how simulation can allow exploration of sequential design’s operating characteristics under a range of scenarios.
nQuery helps make your clinical trials faster, less costly and more successful with tools for sample size calculation - refining Frequentist, Bayesian & Adaptive designs.
Start your unlimited 14-day trial to help design efficient, informative and ethical adaptive trials.
Who is this for?
This will be highly beneficial if you're a biostatistician, scientist, or clinical trial professional that is involved in sample size calculation and the optimization of clinical trials in:
- Pharma and Biotech
- CROs
- Med Device
- Research Institutes
- Regulatory Bodies